News
Apellis Pharmaceuticals won approval from the FDA to expand the use of its drug Empaveli to include treatment for patients ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, ...
Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...
Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...
Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...
A drug from Fulcrum Therapeutics showed promise in a sickle cell study, raising the possibility that a pill could be an ...
Opinion
I’m a neurologist. My brother has schizophrenia. I support making involuntary commitment easierWe don’t hesitate to treat a stroke patient who denies their deficits. Psychiatry must be granted the same clarity and the same clinical urgency," writes a neurologist whose brother has schizophrenia.
Improving how the FDA disseminates already-public information about approved drugs may be unsexy, but it would be a big step ...
NIH plans to shrink the share of grant applications it will award for the remainder of the fiscal year, in some cases by more ...
Researchers are turning to a new approach for early cancer detection, making use of nanoscale biological structures called ...
Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...
Kennedy and advocates have very different views on how his tenure impacts the community of Americans with disabilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results